Q-omics provides the consensus-scored NBPF4 profile across patient tissues and cancer cell-line models. NBPF4 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NBPF4 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, NBPF4 RNA expression shows 6,281 significant pathway-activity associations, with the highest sampling consensus in LIHC. Together, these results highlight UCEC, BRCA, and LIHC as cancer lineages where NBPF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF4 survival associations across molecular data types. NBPF4 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF4 RNA expression–survival associations across cancer types. High NBPF4 expression shows unfavorable associations in UCEC, LUAD, LIHC, KICH and KIRC, but favorable associations in BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for NBPF4 RNA expression.
This table summarizes NBPF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF4 shows lower tumor expression in KICH and higher tumor expression in BRCA, BLCA, LUAD, PAAD and LUSC. The BRCA box plot shows higher NBPF4 RNA expression in tumor versus normal tissue (log2 FC = +0.896, t-test p < 0.001).
This table shows molecular features associated with NBPF4 in patient tissues and cancer cell lines. In patient samples, NBPF4 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, NBPF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
